ERBB2 and glioblastoma: A phase I trial (NCT03383978/CAR2BRAIN) is testing NK-92/5.28.z cells targeting ErbB2 (HER2) in recurrent GBM, investigating safe dosing via intraoperative or reservoir-based delivery, with potential combinations with anti-PD-1 therapy (Li et al. 2018; Burger et al. 2017).